Lyra therapeutics announces first patient dosed in pivotal enlighten i clinical trial of lyr-210 in chronic rhinosinusitis patients

Watertown, mass., feb. 28, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today announced the enrollment of the first patient in the phase 3 enlighten i clinical trial of lyr-210 in adult patients with chronic rhinosinusitis (crs).
LYRA Ratings Summary
LYRA Quant Ranking